The dextromethorphan analog dimemorfan attenuates kainate‐induced seizures via σ1 receptor activation: comparison with the effects of dextromethorphan
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
In a previous study, we demonstrated that a dextromethorphan analog, dimemorfan, has neuroprotective effects. Dextromethorphan and dimemorfan are high‐affinity ligands at σ1 receptors. Dextromethorphan has moderate affinities for phencyclidine sites, while dimemorfan has very low affinities for such sites, suggesting that these sites are not essential for the anticonvulsant actions of dimemorfan. Kainate (KA) administration (10 mg kg−1, i.p.) produced robust convulsions lasting 4–6 h in rats. Pre‐treatment with dimemorfan (12 or 24 mg kg−1) reduced seizures in a dose‐dependent manner. Dimemorfan pre‐treatment also attenuated the KA‐induced increases in c‐fos/c‐jun expression, activator protein (AP)‐1 DNA‐binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus. These effects of dimemorfan were comparable to those of dextromethorphan. The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective σ1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to σ1 receptor‐activated modulation of AP‐1 transcription factors. We asked whether dimemorfan produces the behavioral side effects seen with dextromethorphan or dextrorphan (a phencyclidine‐like metabolite of dextromethorphan). Conditioned place preference and circling behaviors were significantly increased in mice treated with phencyclidine, dextrorphan or dextromethorphan, while mice treated with dimemorfan showed no behavioral side effects. Our results suggest that dimemorfan is equipotent to dextromethorphan in preventing KA‐induced seizures, while it may lack behavioral effects, such as psychotomimetic reactions. British Journal of Pharmacology (2005) 144, 908–918. doi:10.1038/sj.bjp.0705998
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bohmann, D., Bos, T. J., Admon, A., Nishimura, T., Vogt, P. K., & Tjian, R. (1987) · Science · doi:10.1126/science.2825349 · Cited by 1,321 · cited 1×
“The cRNA probes for c-fos (Curran et al., 1987), c-jun (Boham et al., 1987) and GAPDH (Fort et al., 1985) were synthesized in vitro from linearized expression vector using DIG-UTP, as suggested by the manufacturer (Boehringer Mannheim, Germany).”
MethodPharmacological Analysis of Sterol Δ8-Δ7 Isomerase Proteins with [3H]Ifenprodil
Moebius, F. F., Reiter, R. J., Bermoser, K., Glossmann, H., Cho, S. Y., & Paik, Y.-K. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.3.591 · Cited by 81
Cited by
Tzschentke, T. M. (2007) · Addiction Biology · doi:10.1111/j.1369-1600.2007.00070.x · Cited by 1,336
Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands
Cobos, E., Entrena, J., Nieto, F., Cendan, C., & Pozo, E. (2008) · Current Neuropharmacology · doi:10.2174/157015908787386113 · Cited by 376
Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders
Nguyen, L., Thomas, K. L., Lucke-Wold, B. P., Cavendish, J. Z., Crowe, M. S., & Matsumoto, R. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.016 · Cited by 141
Murrough, J. W., Stade, E., Sayed, S., Ahle, G., Kiraly, D. D., Welch, A., Collins, K. A., Soleimani, L., Iosifescu, D. V., & Charney, D. S. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.04.072 · Cited by 62
Vavers, E., Zvejniece, L., & Dambrova, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106771 · Cited by 30
Metadata
- Authors
- Shin, E., Nah, S., Kim, W., Ko, K. H., Jhoo, W., Lim, Y., Cha, J. Y., Chen, C., & Kim, H.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2005-04
- Volume
- 144
- Issue
- 7
- Pages
- 908-918
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2000982876
- Cited by
- 66
- References
- 2
- FWCI
- 1.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.